| 000 | 01862 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250518052900.0 | ||
| 264 | 0 | _c20191231 | |
| 008 | 201912s 0 0 eng d | ||
| 022 | _a1422-0067 | ||
| 024 | 7 |
_a10.3390/ijms20153751 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDanieau, Geoffroy | |
| 245 | 0 | 0 |
_aNew Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies? _h[electronic resource] |
| 260 |
_bInternational journal of molecular sciences _cJul 2019 |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBone Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aBone and Bones |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aGene Expression Regulation, Neoplastic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLymphatic Metastasis |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xmethods |
| 650 | 0 | 4 |
_aNeovascularization, Pathologic _xgenetics |
| 650 | 0 | 4 |
_aOncogene Proteins, Fusion _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aOsteosarcoma _xdrug therapy |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-ets _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aRNA-Binding Protein EWS _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aSarcoma, Ewing _xdrug therapy |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aTumor Microenvironment _xdrug effects |
| 650 | 0 | 4 |
_aWnt Signaling Pathway _xdrug effects |
| 650 | 0 | 4 | _aYoung Adult |
| 650 | 0 | 4 |
_abeta Catenin _xantagonists & inhibitors |
| 700 | 1 | _aMorice, Sarah | |
| 700 | 1 | _aRédini, Françoise | |
| 700 | 1 | _aVerrecchia, Franck | |
| 700 | 1 | _aRoyer, Bénédicte Brounais-Le | |
| 773 | 0 |
_tInternational journal of molecular sciences _gvol. 20 _gno. 15 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3390/ijms20153751 _zAvailable from publisher's website |
| 999 |
_c29964242 _d29964242 |
||